Cancer drug lenalidomide tested for HIV-Linked kaposi sarcoma
NCT ID NCT01282047
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the drug lenalidomide in 12 people with HIV who had Kaposi sarcoma, a type of cancer. Participants took lenalidomide pills for 21 days each month. The study aimed to see if the drug could shrink tumors, but it was stopped early, so the results are not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenalidomide
- What this could lead to
- If it works, this could point toward a new treatment option for Kaposi sarcoma in people with HIV.
- What could go wrong
- This was a very small, early-phase trial that was terminated early, so results are limited. Lenalidomide can cause serious side effects like low blood counts and blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION ASSOCIATED KAPOSI DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Valerie Martinez
Clamart, France, 92141, France